Cite
HARVARD Citation
Conduit, C. et al. (2022). GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol). Therapeutic advances in medical oncology. p. . [Online].